Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity†
Scott M. Wilhelm
Bayer HealthCare Pharmaceuticals, Montville, NJ
Search for more papers by this authorChristopher A. Carter
Bayer HealthCare Pharmaceuticals, Montville, NJ
Search for more papers by this authorGunnar Schütz
Global Drug Discovery, Bayer Schering Pharma AG, Berlin, Germany
Search for more papers by this authorKarl-Heinz Thierauch
Global Drug Discovery, Bayer Schering Pharma AG, Berlin, Germany
Search for more papers by this authorCorresponding Author
Dieter Zopf
Global Drug Discovery, Bayer Schering Pharma AG, Berlin, Germany
Tel: +49 30 468 14531
Global Drug Discovery, Bayer Schering Pharma AG, Müllerstrasse 178, Berlin 13342, GermanySearch for more papers by this authorScott M. Wilhelm
Bayer HealthCare Pharmaceuticals, Montville, NJ
Search for more papers by this authorChristopher A. Carter
Bayer HealthCare Pharmaceuticals, Montville, NJ
Search for more papers by this authorGunnar Schütz
Global Drug Discovery, Bayer Schering Pharma AG, Berlin, Germany
Search for more papers by this authorKarl-Heinz Thierauch
Global Drug Discovery, Bayer Schering Pharma AG, Berlin, Germany
Search for more papers by this authorCorresponding Author
Dieter Zopf
Global Drug Discovery, Bayer Schering Pharma AG, Berlin, Germany
Tel: +49 30 468 14531
Global Drug Discovery, Bayer Schering Pharma AG, Müllerstrasse 178, Berlin 13342, GermanySearch for more papers by this authorPotential conflicts of interest: SMW, LA, GS, KHT and DZ are currently employees of the Bayer HealthCare organisation.
Abstract
Angiogenesis, a critical driver of tumor development, is controlled by interconnected signaling pathways. Vascular endothelial growth factor receptor (VEGFR) 2 and tyrosine kinase with immunoglobulin and epidermal growth factor homology domain 2 play crucial roles in the biology of normal and tumor vasculature. Regorafenib (BAY 73-4506), a novel oral multikinase inhibitor, potently inhibits these endothelial cell kinases in biochemical and cellular kinase phosphorylation assays. Furthermore, regorafenib inhibits additional angiogenic kinases (VEGFR1/3, platelet-derived growth factor receptor-β and fibroblast growth factor receptor 1) and the mutant oncogenic kinases KIT, RET and B-RAF. The antiangiogenic effect of regorafenib was demonstrated in vivo by dynamic contrast-enhanced magnetic resonance imaging. Regorafenib administered once orally at 10 mg/kg significantly decreased the extravasation of Gadomer in the vasculature of rat GS9L glioblastoma tumor xenografts. In a daily (qd)×4 dosing study, the pharmacodynamic effects persisted for 48 hr after the last dosing and correlated with tumor growth inhibition (TGI). A significant reduction in tumor microvessel area was observed in a human colorectal xenograft after qd×5 dosing at 10 and 30 mg/kg. Regorafenib exhibited potent dose-dependent TGI in various preclinical human xenograft models in mice, with tumor shrinkages observed in breast MDA-MB-231 and renal 786-O carcinoma models. Pharmacodynamic analyses of the breast model revealed strong reduction in staining of proliferation marker Ki-67 and phosphorylated extracellular regulated kinases 1/2. These data demonstrate that regorafenib is a well-tolerated, orally active multikinase inhibitor with a distinct target profile that may have therapeutic benefit in human malignancies.
Supporting Information
Additional Supporting Information may be found in the online version of this article.
| Filename | Description |
|---|---|
| IJC_25864_sm_suppfig01.eps233.5 KB | Supporting Information Figure 1 |
| IJC_25864_sm_suppfig02.eps246 KB | Supporting Information Figure 2 |
| IJC_25864_sm_suppfig03.eps238.8 KB | Supporting Information Figure 3 |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
References
- 1 Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249–57.
- 2 Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 2004; 9 (Suppl 1): 2–10.
- 3 Fong GH, Rossant J, Gertsenstein M, Breitman ML. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 1995; 376: 66–70.
- 4 Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu X-F, Breitman ML, Schuh AC. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 1995; 376: 62–6.
- 5 Hasskarl J. Sorafenib. Recent Results Cancer Res 2010; 184: 61–70.
- 6 Goodman VL, Rock EP, Dagher R, Ramchandani RP, Abraham S, Gobburu JVS, Booth BP, Verbois SL, Morse DE, Liang CY, Chidambaram N, Jiang JX, et al. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res 2007; 13: 1367–73.
- 7 Ranieri G, Patruno R, Ruggieri E, Montemurro S, Valerio P, Ribatti D. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic. Curr Med Chem 2006; 13: 1845–57.
- 8 Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000; 407: 242–8.
- 9 Acevedo VD, Ittmann M, Spencer DM. Paths of FGFR-driven tumorigenesis. Cell Cycle 2009; 8: 580–8.
- 10 Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003; 111: 1287–95.
- 11 Augustin HG, Koh GY, Thurston G, Alitalo K. Control of vascular morphogenesis and homeostasis through the angiopoietin–Tie system. Nat Rev Mol Cell Biol 2009; 10: 165–77.
- 12 Huang J, Bae J-O, Tsai JP, Kadenhe-Chiweshe A, Papa J, Lee A, Zeng S, Kornfeld ZN, Ullner P, Zaghloul N, Ioffe E, Nandor S, et al. Angiopoietin-1/Tie-2 activation contributes to vascular survival and tumor growth during VEGF blockade. Int J Oncol 2009; 34: 79–87.
- 13 Bach F, Uddin FJ, Burke D. Angiopoietins in malignancy. Eur J Surg Oncol 2007; 33: 7–15.
- 14 Saito M, Watanabe J, Fujisawa T, Kamata Y, Nishimura Y, Arai T, Miyamoto T, Obokata A, Kuramoto H. Angiopoietin-1, 2 and Tie2 expressions in endometrial adenocarcinoma—the Ang2 dominant balance up-regulates tumor angiogenesis in the presence of VEGF. Eur J Gynaecol Oncol 2006; 27: 129–34.
- 15 Szarvas T, Jäger T, Tötsch M, Vom Dorp F, Kempkensteffen C, Kovalszky I, Romics I, Ergün S, Rübben H. Angiogenic switch of angiopoietins–Tie2 system and its prognostic value in bladder cancer. Clin Cancer Res 2008; 14: 8253–62.
- 16 Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010; 10: 116–29.
- 17 Fletcher JA, Rubin BP. KIT mutations in GIST. Curr Opin Genet Dev 2007; 17: 3–7.
- 18 Lanzi C, Cassinelli G, Nicolini V, Zunino F. Targeting RET for thyroid cancer therapy. Biochem Pharmacol 2009; 77: 297–309.
- 19 Bayer Pharmaceutical Corporation. Fluoro substituted omega- carboxylaryl diphenyl urea for the treatment and prevention of diseases and conditions. US2004023500, 2005.
- 20 Bold G, Altmann K-H, Frei J, Lang M, Manley PW, Traxler P, Wietfeld B, Brüggen J, Buchdunger E, Cozens R, Ferrari S, Furet P, et al. New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis. J Med Chem 2000; 43: 2310–23.
- 21 Sun L, Liang C, Shirazian S, Zhou Y, Miller T, Cui J, Fukuda JY, Chu J-Y, Nematalla A, Wang X, Chen H, Sistla A, et al. Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J Med Chem 2003; 46: 1116–9.
- 22 Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099–109.
- 23 Chang YS, Adnane J, Trail PA, Levy J, Henderson A, Xue D, Bortolon E, Ichetovkin M, Chen C, McNabola A, Wilkie D, Carter CA, et al. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol 2007; 59: 561–74.
- 24 Lux ML, Rubin BP, Biase TL, Chen C-J, Maclure T, Demetri G, Xiao S, Singer S, Fletcher CDM, Fletcher JA. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol 2000; 156: 791–5.
- 25 Carlomagno F, Salvatore D, Santoro M, Defranciscis V, Quadro L, Panariello L, Colantuoni V, Fusco A. Point mutation of the Ret proto-oncogene in the TT human medullary thyroid carcinoma cell line. Biochem Biophys Res Commun 1995; 207: 1022–8.
- 26
Su M-Y,
Wang Z,
Nalcioglu O.
Investigation of longitudinal vascular changes in control and chemotherapy-treated tumors to serve as therapeutic efficacy predictors.
J Magn Reson Imaging
1999;
9:
128–37.
10.1002/(SICI)1522-2586(199901)9:1<128::AID-JMRI17>3.0.CO;2-E CAS PubMed Web of Science® Google Scholar
- 27 Zopf D, Heinig R, Schütz G, Thierauch K-H, Hirth-Dietrich C, Hafner F-T, Christensen O, Lin T, Wilhelm S, Radtke M. Regorafenib (BAY 73-4506): identification of clinically relevant metabolites and their preclinical pharmacology. Poster 1666 presented at 101st Annual Meeting of the American Association for Cancer Research, Washington, DC, April 17-21, 2010.
- 28 Dumas J, Smith RA, Lowinger TB. Recent developments in the discovery of protein kinase inhibitors from the urea class. Curr Opin Drug Discov Devel 2004; 7: 600–16.
- 29 Wilhelm S, Adnane J, Hirth-Dietrich C, Ehrlich P, Lynch M. Preclinical characterization of BAY 73-4506: a kinase inhibitor with broad spectrum antitumor activity targeting oncogenic and angiogenic kinases. Abstract B260 presented at the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, San Francisco, USA, October 22–26, 2007.
- 30 Fabian MA, Biggs WH, III, Treiber DK, Atteridge CE, Azimioara MD, Benedetti MG, Carter TA, Ciceri P, Edeen PT, Floyd M, Ford JM, Galvin M, et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 2005; 23: 329–36.
- 31 Liu Y, Gray NS. Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol 2006; 2: 358–64.
- 32 Moon WS, Rhyu KH, Kang MJ, Lee DG, Yu HC, Yeum JH, Koh GY, Tarnawski AS. Overexpression of VEGF and angiopoietin 2: a key to high vascularity of hepatocellular carcinoma? Mod Pathol 2003; 16: 552–7.
- 33 Etoh T, Inoue H, Tanaka S, Barnard GF, Kitano S, Mori M. Angiopoietin-2 is related to tumor angiogenesis in gastric carcinoma: possible in vivo regulation via induction of proteases. Cancer Res 2001; 61: 2145–53.
- 34 Imanishi Y, Hu B, Jarzynka MJ, Guo P, Elishaev E, Bar-Joseph I, Cheng S-Y. Angiopoietin-2 stimulates breast cancer metastasis through the a5b1 integrin-mediated pathway. Cancer Res 2007; 67: 4254–63.
- 35 Oliner J, Min H, Leal J, Yu D, Rao S, You E, Tang X, Kim H, Meyer S, Han SJ, Hawkins N, Rosenfeld R, et al. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 2004; 6: 507–16.
- 36 Herbst RS, Hong D, Chap L, Kurzrock R, Jackson E, Silverman JM, Rasmussen E, Sun Y-N, Zhong D, Hwang YC, Evelhoch JL, Oliner JD, et al. Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol 2009; 27: 3557–65.
- 37 Mita AC, Takimoto CH, Mita M, Tolcher A, Sankhala K, Sarantopoulos J, Valdivieso M, Wood L, Rasmussen E, Sun YN, Zhong ZD, Bass MB, et al. Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors. Clin Cancer Res 2010; 16: 3044–56.
- 38 Padhani AR, Leach MO. Antivascular cancer treatments: functional assessments by dynamic contrast-enhanced magnetic resonance imaging. Abdom Imaging 2005; 30: 325–42.
- 39 Fukumura D, Jain RK. Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. Microvasc Res 2007; 74: 72–84.
- 40 Tsai JH, Lee WMF. Tie2 in tumor endothelial signaling and survival: implications for antiangiogenic therapy. Mol Cancer Res 2009; 7: 300–10.
- 41 Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008; 8: 592–603.
- 42 Lucio-Eterovic AK, Piao Y, de Groot JF. Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy. Clin Cancer Res 2009; 15: 4589–99.
- 43 Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005; 8: 299–309.
- 44 Crawford Y, Kasman I, Yu L, Zhong C, Wu X, Modrusan Z, Kaminker J, Ferrara N. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell 2009; 15: 21–34.
- 45 Lewis CE, De Palma M, Naldini L. Tie2-expressing monocytes and tumor angiogenesis: regulation by hypoxia and angiopoietin-2. Cancer Res 2007; 67: 8429–32.
- 46 Prenen H, Cools J, Mentens N, Folens C, Sciot R, Schoffski P, Van Oosterom A, Marynen P, Debiec-Rychter M. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. Clin Cancer Res 2006; 12: 2622–7.
- 47 Strumberg D, Scheulen ME, Frost A, Büchert M, Christensen O, Wagner A, Heinig R, Fasol U, Mross K. Phase I study of BAY 73-4506, an inhibitor of oncogenic and angiogenic kinases, in patients with advanced refractory colorectal carcinoma (CRC). J Clin Oncol (Meeting Abstracts) 2009; 27: 161s. Abstract 3560.
- 48
Eisen T,
Joensuu H,
Nathan P,
Harper P,
Wojtukiewicz M,
Nicholson S,
Bahl A,
Tomczak P,
Wagner A,
Quinn D.
Phase II trial of the oral multikinase inhibitor BAY 73-4506 as 1st-line therapy in patients with metastatic or unresectable renal cell cancer (RCC).
Eur J Cancer
2009;
7 (Suppl):
424. Abstract O-7105.
10.1016/S1359-6349(09)71438-7 Google Scholar
- 49 Reusch P, Barleon B, Weindel K, Martiny-Baron G, Gödde A, Siemeister G, Marmé D. Identification of a soluble form of the angiopoietin receptor TIE-2 released from endothelial cells and present in human blood. Angiogenesis 2001; 4: 123–31.
- 50 Masters JR, Thomson JA, Daly-Burns B, Reid YA, Dirks WG, Packer P, Toji LH, Ohno T, Tanabe H, Arlett CF, Kelland LR, Harrison M, et al. Short tandem repeat profiling provides an international reference standard for human cell lines. Proc Natl Acad Sci USA 2001; 98: 8012–7.
Citing Literature
